| 7.58 -0.08 (-1.04%) | 03-02 16:00 | |||||||||||||
|
|
| Short term |  |
|||
| Mid term |  |
|||
| Targets | 6-month : | 9.8  |
1-year : | 11.97 |
| Resists | First : | 8.39 |
Second : | 10.25 |
| Pivot price | 7.39 |
|||
| Supports | First : | 5.4 | Second : | 4.49 |
| MAs | MA(5) : | 7.39 |
MA(20) : | 7.74 |
| MA(100) : | 9.77 |
MA(250) : | 15.24 |
|
| MACD | MACD : | -0.7 |
Signal : | -0.8 |
| %K %D | K(14,3) : | 52.1 |
D(3) : | 47.5 |
| RSI | RSI(14): 46 |
|||
| 52-week | High : | 62.5 | Low : | 4.62 |
Price has closed above its short-term moving average. Short-term moving average is currently below mid-term; and below long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BEARISH in mid-long term.[ INTS ] has closed below upper band by 46.6%. Bollinger Bands are 20.7% narrower than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 7.71 - 7.75 | 7.75 - 7.78 |
| Low: | 7.4 - 7.45 | 7.45 - 7.49 |
| Close: | 7.5 - 7.58 | 7.58 - 7.65 |
Intensity Therapeutics, Inc., a clinical-stage biotechnology company, engages in the discovery, development, and commercialization of cancer drugs to treat solid tumors. The company's lead product candidate is INT230-6, which is in Phase 2 clinical trial for the treatment of refractory solid tumors; and pancreatic, colon, bile duct, squamous cell carcinoma, sarcoma, breast, and liver cancers. It has a collaboration agreement with Merck Sharpe & Dohme Corp. to evaluate the combination of INT230-6 and Keytruda in patients with advanced pancreatic, colon, squamous cell, and bile duct malignancies; Bristol-Myers Squibb Company to evaluate the combination of INT230-6 with Yervoy in patients with advanced liver, breast, and sarcoma cancers; and Ottawa Hospital Research Institute and the Ontario Institute of Cancer Research to study INT230-6 in a randomized controlled neoadjuvant phase II study in women with early-stage breast cancer. The company was founded in 2012 and is headquartered in Westport, Connecticut.
Sun, 01 Mar 2026
INTS Financials: Income Statement, Balance Sheet & Cash Flow - Stock Titan
Sat, 28 Feb 2026
INTS.O Technical Analysis & Stock Price Forecast - Intellectia AI
Thu, 26 Feb 2026
INTS.O Stock News Today | Earnings, Events & Price Alerts - Intellectia AI
Wed, 25 Feb 2026
Intensity Therapeutics (INTS) Price Target Increased by 2,399.98% to 74.38 - Nasdaq
Fri, 13 Feb 2026
Intensity Therapeutics Announces Reverse Stock Split - PR Newswire
Tue, 13 Jan 2026
Intensity Therapeutics Highlights 2025 Milestones and Outlines 2026 Strategic Priorities - PR Newswire
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Outperform |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Outperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 60 (M) |
| Shares Float | 2 (M) |
| Held by Insiders | 8.3 (%) |
| Held by Institutions | 8 (%) |
| Shares Short | 1,160 (K) |
| Shares Short P.Month | 1,870 (K) |
| EPS | -13.75 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 3.68 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | -101.7 % |
| Return on Equity (ttm) | -234.7 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | 0 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -10 (M) |
| Levered Free Cash Flow | -5 (M) |
| PE Ratio | -0.56 |
| PEG Ratio | 0 |
| Price to Book value | 2.05 |
| Price to Sales | 0 |
| Price to Cash Flow | -47.93 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|